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The physical properties of particles used in radiation therapy, such as protons, have been well characterized,
and their dose distributions are superior to photon-based treatments. However, proton therapy may also
have inherent biologic advantages that have not been capitalized on. Unlike photon beams, the linear energy
transfer (LET) and hence biologic effectiveness of particle beams varies along the beam path. Selective
placement of areas of high effectiveness could enhance tumor cell kill and simultaneously spare normal
tissues. However, previous methods for mapping spatial variations in biologic effectiveness are
time-consuming and often yield inconsistent results with large uncertainties. Thus the data needed to
accurately model relative biological effectiveness to guide novel treatment planning approaches are limited.
We usedMonte Carlomodeling and high-content automated clonogenic survival assays to spatiallymap the
biologic effectiveness of scanned proton beams with high accuracy and throughput while minimizing
biological uncertainties. We found that the relationship between cell kill, dose, and LET, is complex and
non-unique. Measured biologic effects were substantially greater than in most previous reports, and
non-linear surviving fraction response was observed even for the highest LET values. Extension of this
approach could generate data needed to optimize proton therapy plans incorporating variable RBE.
I nterest in particle therapy, particularly proton therapy, has been increasing. The number of treatment centersin the United States alone is expected to double over the next 5–10 years. Although initial clinical results arepromising, the rapid expansion of particle therapy is controversial given its high cost and the need for
randomized trials to assess the clinical benefits of proton therapy compared with standard photon (X-ray) based
treatments1–3.
Currently the widespread interest in proton therapy is driven by the physical properties of particle therapy,
which allow greater sparing of normal tissues from excess radiation. The relevant physical properties stem from
the fact that protons and other charged particles continuously lose energy as they traverse through tissue, with the
rate of energy loss increasing as the particles slow. This phenomenon results in a dose deposition profile in which
doses are low at the entrance into tissue, higher near the end of the range, and drop to near zero abruptly
thereafter. The highest point of the dose deposition curve is known as the Bragg peak. In principle, these physical
dose-deposition characteristics of particle therapy offer significant potential to enhance the therapeutic ratio
compared with conventional modes of radiation therapy.
Although the physical properties of particles such as protons are well understood, much remains to be learned
of their unique biologic effects. A large amount of research has demonstrated that particles generally have higher
relative biological effectiveness (RBE) than photons (which by definition have an RBE of 1 when produced by
Cobalt-60) towards the end of their range. This increased RBE indicates that particles are more biologically
effective at inducing cell death than are photons, which underscores their potential for treating radiation-resistant
tumors4,5. Heavier particles, such as carbon ions, have a significantly higher RBE than photons, with typical values
ranging between 2 and 4 depending on the location along the beampath6,7. Protons, being relatively light particles,
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have an RBE closer to that of photons. In the current clinical practice
of proton therapy, the RBE is assumed to have a generic, spatially
invariant, constant value of 1.18.
This assumption has been justified based on numerous in vitro and
in vivo experiments carried out under relatively limited conditions
using older delivery techniques (e.g., high doses per fraction, passive
scattering)8. Although numerous, existing experimental data tend to
be inconsistent and involve large uncertainties, a factor that is often
used to justify the continued use of averaged RBE value of 1.19. Even
with high uncertainties and inconsistencies, many experiments have
shown that the RBE of proton beams can vary considerably along the
beam path and as a function of dose, but these potential variations in
RBE are not accounted for in clinical treatment planning sys-
tems10–12. Thus, the concept of a generic RBE value for proton ther-
apy is increasingly coming under scrutiny. Deeper understanding of
the unique biologic effects of protons, combined with advances in
planning delivery techniques, could considerably expand the thera-
peutic index of proton therapy.
Further, as delivery modalities progress, the opportunity arises to
capitalize on the RBE variability of both protons and other ions.
Historically, most clinical particle treatments were delivered with
passive scattering technology, where a thin beam is scattered laterally
and modulated longitudinally to produce a volume of uniform dose,
comprising superposition of multiple Bragg peaks into what is
known as the spread-out Bragg peak (SOBP)11. This volume is
shaped by introducing materials into the beam to conform it to
the three-dimensional shape of the target. In this delivery method,
the highest-intensity Bragg curves contribute most of the dose to the
formation of the distal edges of beams, which commonly lie within
normal tissues beyond the target tumor volume.
Newer techniques use magnetically scanned thin pristine beams
(‘‘beamlets’’) of particles with sequences of energies to produce dose
distribution patterns to plan and deliver the most advanced form of
particle therapy, intensity-modulated particle therapy (IMPT).
IMPT involves sophisticated optimization techniques to adjust
intensities and energies of incident pristine beams to balance the
need to deliver maximum doses to tumor targets while maximally
sparing nearby normal tissues.
IMPT has the potential to exploit the higher RBE of protons or
other particles around the Bragg peak by preferentially placing the
most biologically effective portions of the beam inside the target
volume and away from normal structures. This is in contrast to
current delivery techniques, in which the treatment is optimized
solely to create a uniform dose in the target volume without consid-
eration of the varying biological effectiveness of the particles in the
beam. This preferential placement approach could significantly
increase the differential between doses to target vs. normal tissues.
However, the incorporation of variable RBE into IMPT optimization
requires that accurate models be developed for computing RBE as a
function of dose per fraction, linear energy transfer (LET), and tissue
type, which in turn would require large amounts of accurate data on
RBE. Unfortunately, data for developing these models are limited
and have been difficult to obtain because of numerous complicating
factors such as adequate access to beam time, non-standardized irra-
diations, variations in experimental techniques and reporting as well
as the large span of reported biologic responses9,13.
In a recent comprehensive review, Paganetti systematically ana-
lyzed hundreds of published clonogenic data points to determine a
relevant proton RBE9. That review stated that although the use of an
RBE of 1.1 is acceptable for large clinical SOBPs, the literature does
support increased RBE values of 1.15 at the center, 1.35 at the distal
edge, and 1.7 at the distal falloff of an SOBP. Equally as important, the
review highlights the large spread of the existing clonogenic data and
suggests a need for experimental protocol standardization in addi-
tion to more complete reporting of fit parameters and errors.
Although clearer data reporting is relatively straightforward, the
ideal experimental protocol will require optimization owing to the
multitude of complicating factors in a clonogenic assay alone that
could contribute to the observed data spread.
In this report, we describe our combined use of basic particle
physics and minimization of biological uncertainty to design a
high-throughput system for improving the accuracy of the acquired
biologic data as a function of dose and LET. We report preliminary
results generated with actively scannedmonoenergetic proton beams
as a demonstration of the potential of such an approach. We anticip-
ate that this method will continue to evolve to address multiple
experimental needs, not only for proton biology but also for similar
experiments with other ion species.
Results
Monte Carlo–based design of a customized device to accurately
and efficiently map biologic effects. The spatial energy spectra,
and hence the LET spectra, of a therapeutic proton beam depend
on several factors including incident energy, SOBP width, and
position of measurement within the SOBP as well as the machine-
specific hardware used for scattering and range modulation. We
compared the calculated energy spectra between passively scattered
and scanned beams at three matched locations along the beam paths
and found substantial differences between the two delivery methods
(Fig. 1a–c). The broad energy spectra of passively scattered beams,
particularly the long low-energy tails, could introduce significant
uncertainty in the relationship between biological effect and LET.
To minimize the breadth of the energy and LET spectra, and to
facilitate correlations of biologic effect with LET and dose, we
developed a system using monoenergetic scanned proton beams.
Because LET increases as a function of depth along the Bragg curve,
first slowly and then rapidly, we usedMonte Carlo (MC) simulations
to design an apparatus (jig) to attenuate proton energy in a stepwise
fashion from the incident energy to the end of the range (schematic-
ally illustrated in Fig. 1d). We chose 96-well plates to allow the
simultaneous irradiation of biologic samples to multiple dose-LET
combinations and automated plate processing. The irradiation jig
was designed by grouping the 96 wells into 12 columns of 8 wells
each, such that each of the columns are simultaneously exposed to a
different combination of dose and LET, thus enabling the acquisition
of 12 times the amount of data from a single exposure. All of the wells
in a column are intended to receive the same dose-LET combination
(Fig. 1e). The resulting design can be considered a multi-step range
shifter consisting of 12 steps. The thickness of steps varies from 0 to a
maximum value producing protons of increasing LET; the thickest
steps irradiate the cells with the portion of the Bragg curve from just
before to just beyond the Bragg peak. The jig was custom-fabricated
from Lucite and directly mounts into the snout of the scanning beam
gantry. The biologic sample plate is placed on top of the jig with the
beam directed upwards (Fig. 1f). The thickness of the material inter-
posed in the proton beam path initially varies in large steps and then
in increasingly finer increments as the end of the proton range
approaches and at points beyond. This approach was taken to
increase the resolution in regions of high dose and LET gradients.
MC calculations indicated that the jig did not appreciably alter the
profiles of the energy spectra (Supplementary Fig. 1).
Validation of spatial accuracy and irradiation of samples.To verify
the precision of the jig setup and radiation delivery in relation to the
Bragg curve, a scan pattern consisting of 441 spots of a 79.7-MeV
proton beamwas generated to form a 203 20 cm2 field. The field was
found to be uniform over an area of 12 3 13 cm2, large enough to
cover the biological sample area of 10.8 3 7.2 cm2 (Fig. 2a&b). The
respective column doses to a simulated cell layer were also found to
be within the statistical uncertainty of the MC simulations (6,1%).
To determine the location of the Bragg peak, we exposed a stack of
twelve EBT3 films (each 268 mm thick) placed on top of an empty
www.nature.com/scientificreports
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96-well plate inserted into the jig (Fig. 2c). Optical densitometry
analysis revealed that the location of the Bragg peak position
changed from film to film depending on the total intervening
thickness. To allow three points of measurement in the high-dose
gradient region beyond the Bragg peak, we sought to place the peak in
the cell layer of column 9. We found that the peak was located at
column 9 for the fourth film, indicating that insertion of three films
below the sample plate would provide the desired shift (Fig. 2d).
Subsequently, three EBT3 films were placed below the sample plate
in all MC simulations and irradiations for clonogenic assays. In the
presence of the jig, the dose varied across the columns of the plate
from entrance to the peak by a factor of 5.5. Two subsequent
validation tests were performed 2 months apart using a calibrated
clinical plane-parallel ionization chamber and the jig setup. The ion
chamber was inserted into a Lucite holder and irradiated atop the
exact jig setup to be used for future biologic sample irradiation. The
MC-predicted dose and ion chamber measurement were found to
differ by 0.35%, which is within the expected setup uncertainty from
our sensitivity analysis (Supplementary Fig. 2; Supplementary Table
2). This setup was then used to irradiate 96-well plates with biologic
samples to a range of entrance doses, thus producing a set of samples
exposed to a matrix of dose-LET combinations (Fig. 1e).
Mapping variations in biologic effect with high-content
automated assays. To establish the feasibility of our approach and
relate our findings to those of historical studies, we used dose-
averaged LET-dependent cancer cell line clonogenic survival as
the primary endpoint for our initial experiments. We adapted
high-content screening techniques for higher throughput and used
specific techniques to increase the accuracy of the data generated14.
We first benchmarked the high-content system by comparing
clonogenic assay results obtained from both the high-content and
traditional method of manually counting colonies in 6-well plates of
cultured H460 non-small cell lung cancer (NSCLC) cells (Fig. 3a&b).
The H460 cell line was chosen for its exceptional clonogenicity and
its doubling time, which we found to be 19 hours (in agreement with
published values)15,16. Log-phase H460 cells were plated into either
96-well plates (0.33 cm2 growth area per well) or 6-well plates (9.5
cm2 growth area per well) from the same stock solution at a seeding
density of 100 cells per well for the 96-well plates and a range of
concentrations for the 6-well plates. The cells were allowed to attach
and normalize for 8–10 hours before being irradiated. Radiation was
delivered with a 137Cs irradiator. Three different passages of the cell
line were used to calculate the average surviving fraction (SF) with a
single 96-well plate at each dose level for the high-content method,
Figure 1 | Rationale for using the scanned monoenergetic proton beams for biology experiments and design of the irradiation device. (a) Depth-dose
profiles for a 79.7-MeV scanned proton beam vs. a matched passively scattered beam of the same range with a 3-cm spread-out Bragg peak (SOBP)
in water. (b) Energy spectra of protons at three points A, B, C within the scattered beam marked in panel (a). (c) Corresponding energy spectra for the
monoenergetic 79.7-MeV scanned beam. (d) Schematic diagramof the irradiation device (jig) concept illustrating the strategy for the column-by-column
simultaneous irradiation of biological samples in the 96-well plate with protons at different points on the pristine Bragg curve. Gray bars indicate Lucite;
red, culture medium. The stepped construction is designed to match the columns of a 96-well plate and serves to vary position along the Bragg curve,
although only 9 columns are shown in the illustration and the step dimensions are not to scale. (e) Dose and LET distributions in the cell layers, positioned
atop the jig, were computed usingMonte Carlo simulations. The relative dose results shown were normalized to the entrance dose in column 1 in the 96-
well plate. The LET shown is dose-averaged LET. The associated errors for both dose and LET were obtained from a sensitivity analysis of experimental
setup uncertainties. The thickness of the 12 steps in the jig was selected according to the variations of dose and LET along the Bragg curve. Column 9 was
aligned with the Bragg peak by inserting three films of thickness 268 mm each. An exposed and processed 96-well plate is shown at the bottom of the panel
to illustrate the dose-LET effect of cell kill. (f) The jig directly mounted onto the scanning beam gantry. The 96-well plates are inserted into a precisely
milled slot in the jig holder designed to minimize positioning errors. Protons are incident from below.
www.nature.com/scientificreports
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or with 6 replicates for each dose per experiment for the traditional
method. After irradiation, the cells were allowed to grow until
sufficient colony formation was observed in the control conditions
(5 days for the high-content system and 10–12 days for the
traditional method) and then fixed and stained. Scoring, either by
manual counting for the traditional method or with an IN Cell
Analyzer 6000 for the high-content system (Fig. 3b), showed good
correlation between techniques, with a non-statistically significant
difference between the curves (P50.315, extra sum-of-squares F test;
Fig. 3c).
We next processed plates for exposure to protons using the jig.
Exponentially growing H460 cells were detached, automatically
counted, diluted, and plated into 96-well plates. Plates were seeded
at 100 cells per well from the same stock solution using an automated
plater. After either photon (137Cs) or proton irradiation, plates were
cultured until colony formation, at which time they were stained and
prepared for readout and subsequent survival analysis. The results of
our high-content proton experiment revealed that irradiation with
increasing LETs resulted in a marked decrease in cell survival
(Fig. 3d). This trend was either obscured or not present at the lower
LET values in the plateau region of the Bragg curve, but it was espe-
cially pronounced for the LET values at and beyond the Bragg peak
(Fig. 3d). Data fitting found that the SF at a dose of 2 Gy (SF2) for the
H460 cells was 0.40 for the lowest LET tested (0.9 keV/mm) and 0.29
for protonswith anLETof 10.8 keV/mmat the Bragg peak. Beyond the
Bragg peak, in high-LET areas, we found still lower SF2 values of 0.10
for 15.2 keV/mm, 0.021 for 17.7 keV/mm, and 0.0037 for 19.0 keV/mm.
These initial results with the H460 cell line prompted us to further
assess our method. To obtain higher-dose data we used the p53-
mutant NSCLC line, H1437, which is resistant to apoptosis17. A
subsequent experiment with H1437 cells corroborated the trend seen
with the H460 cells (Fig. 3e). Calculated SF2s were between 0.70 and
0.79 for the low LETs tested (0.9 to 5.1 keV/mm), 0.63 for 10.8 keV/
mm, 0.47 for 15.2 keV/mm, 0.29 for 17.7 keV/mm, and 0.16 for 19.0
keV/mm using the data fits to the H1437 dataset. Table 1 contains
detailed information on the a and b fit parameters and the recorded
RBE values at 10% SF vs. 137Cs for the clonogenic survival plots.
Plotting the RBE vs. LET for the two cell lines revealed a nonlinear
response over the tested range where the RBE scaled in a biphasic
manner (Fig. 4a).
To demonstrate the applicability of the developed system for use
with assays other than clonogenic survival, we next compared DNA
double-strand break induction (measured as cH2AX foci formation)
between low- and high-LET regions in the H460 cells. As predicted,
in high-LET regions, more foci were present 2 hours after irradiation
(Fig. 4b). The overall dose-averaged number of cH2AX foci per
nucleus was found to be significantly lower at 3.57 6 0.25 for 4.6
keV/mm protons versus an average of 7.02 6 0.44 foci per nucleus at
17.3 keV/mm (P , 0.0001, Mann-Whitney unpaired t test).
Discussion
We found that an integrated physics and biology approach, coupled
with high-throughput techniques, can be used to systematically map
biologic responses to actively scanned proton beams as a function of
Figure 2 | Uniformity of the scanning field and verification of distal edge placement. (a) Dose profile along the central longitudinal axis in the isocenter
plane, resulting from a 20 3 20 cm2 uniform scan pattern with 3.5-cm full-width at half-maximum (FWHM) spots spaced 1 cm apart, measured with a
1,020 chamber MatriXX system (IBA I’mRTMatriXX, Schwarzenbruck, Germany). The field width between the 98% and 100% dose levels is 12 cm. (b)
Dose profile along the central lateral axis in the isocenter plane. The field width between the 98% and 100% dose levels is 13 cm and is along the direction
of the wells of columns; the uniformity over the 7.2-cm extent of the 8 wells in each column is 99%–100%. (c) Schematic of the experimental setup for
range verification. A stack of 12 EBT3 films (each 268 mm thick) was placed directly on top of an empty 96-well plate and exposed. (d) Optical
densitometry measurements of individual films made through the center of the well rows indicated that the Bragg peak was at well column 9 for this film,
the fourth in the stack. In addition to verifying the accuracy of penetration of protons, this experiment allowed us to determine the number of films
needed to position one of the columns (number 9) at the Bragg peak and have three points of measurement in the high gradient distal fall-off.
www.nature.com/scientificreports
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dose and LET. In developing this method, we attempted to reduce
sources of uncertainty while simultaneously increasing data output.
Clonogenic assays have been used to assess cellular reproductive
integrity after an insult for more than 50 years18,19. Evolution of the
exact method and understanding of the assay has produced a rich
amount of relevant literature to draw upon. For each of our experi-
ments, cultured cell concentrations were determined by using an
automated cell counter, and all plates were seeded at a constant
density from a single stock solution within 10–15 minutes of one
another by using an automated plater. Use of a single seeding solu-
tion was intended to reduce potential errors in cell counting on
colony formation. Even at the ideal theoretical limit of cell counting
accuracy, the associated counting error for a standard cell solution is
approximately 15%–30%20,21. This fact alone contributes intrinsic
Figure 3 | High-throughput clonogenic assays of H460 and H1437 NSCLC cells. (a) As a benchmark for our 96-well system, we compared cultures
in that format, processed and counted with the IN Cell Analyzer 6000, with those in 6-well plates, counted manually. Characteristic images of each plate
type are shown. (b) Representative images of a single well depicting high-content image processing. (c) Cell survival curves for individual plates of cells
grown in 6-well or 96-well systems, exposed to 137Cs gamma irradiation, and scored by manual or automated processing. Curves were found to be not
statistically different between the techniques (P50.315, extra sum-of-squares F test). Error bars represent standard error of the mean (s.e.m.). (d)
Clonogenic survival plotted as a function of dose and LET for proton irradiation experiments with H460 cells. Error bars for dose were calculated
by sensitivity analysis and SF with s.e.m. (e) Clonogenic survival as a function of dose and LET for proton experiments performed with H1437 cells.
P , 0.0001 for comparisons of 0.9 keV/mm to $10.8 keV/mm, extra sum-of-squares F test.
www.nature.com/scientificreports
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noise to clonogenic data and introduces compounding uncertainty
when the number of cells per dose are counted separately.
All cell lines have inherent biological sensitivities to culturing
conditions that may or may not affect the outcome of a clonogenic
experiment. We attempted to remove or minimize any possible con-
founding factors from our colony readout as follows. Use of a single
seeding solution per experiment requires a single multiplicity cor-
rection, as applicable22. Plating cells before irradiation and allowing
Table 1 | a and b fit parameters and RBE values at 10% surviving fraction.
Cell line:
H460 H1437
LET [keV/mm] a b RBE a b RBE
0.9 0.268 0.097 1.03 0.077 0.028 0.89
1.2 0.226 0.112 1.04 0.136 0.020 0.88
1.6 0.151 0.134 1.05 0.067 0.027 0.85
1.8 0.150 0.134 1.05 0.059 0.038 0.98
1.9 0.166 0.134 1.06 0.094 0.031 0.96
2.3 0.137 0.146 1.07 0.096 0.032 0.97
3.0 0.206 0.125 1.07 0.111 0.033 1.02
5.1 0.117 0.159 1.10 0.034 0.052 1.10
10.8 0.318 0.154 1.28 0.119 0.054 1.26
15.2 0.446 0.341 1.87 0.180 0.095 1.70
17.7 0.596 0.662 2.58 0.328 0.149 2.33
19.0 0.883 0.956 3.28 0.360 0.272 2.98
Photons(137Cs) 0.290 0.083 1.00 0.050 0.041 1.00
Figure 4 | Preliminary analysis of biological assays. (a) RBE vs LET at 10% SF. A nonlinear trend between biological effect and LETwas observed for both
cell lines. RBE error was calculated by propagating the standard error of the a and b fits from Fig. 3 (Supplementary Table 1). (b) H460 cells were plated in
glass-bottom 96-well plates, irradiated, and processed 2 hours later for cH2AX foci staining. Representative images are depicted. Comparing wells
exposed to LETs and doses of 4.6 keV/mm, 2.9 Gy and 17.3 keV/mm, 1.7 Gy, the average nuclear foci per Gy was significantly increased in the high-LET
samples (P , 0.0001, Mann-Whitney unpaired t test). Error bars represent the 95% confidence level.
www.nature.com/scientificreports
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them to reattach and recover from the stresses induced by plating
kept our focus on the effect of radiation on the clonogenicity of
exponentially growing cells23,24. Seeding cells after irradiation adds
factors that contribute to the biological endpoint, resulting in
increased uncertainty. Immediate post-irradiation plating in particu-
lar involves the effects of cell detachment during seeding while the
cells are still repairing radiation-induced damage25. In addition to
anchorage-dependent signaling and morphologic changes adherent
cells undergo during detachment, enzymatic detachment solutions,
such as trypsin, cleave membrane-bound adhesion molecules that
function as major signalers in cellular stress responses, including
apoptosis26–29. Post-irradiation cell detachment can further con-
found determination of RBE because photons and ions have different
effects on cell adhesion and motility30–32. As such, immediate post-
irradiation plating readouts involve coupling the effect of the radi-
ation treatment with cellular reattachment, except in the plating
efficiency control used to determine overall SF levels. Another com-
plicating factor of post-irradiation plating is the possible contri-
bution of potentially lethal damage repair to cell survival
depending on the experimental conditions and timeline19,33–35. For
this work, we used the minimum number of counting steps for a
clonogenic assay, attempted to minimize relative errors by ensuring
the exchangeability of inter-experiment plates, and removed com-
plicating biological processes from the readout of colony formation.
Our high-throughput method presented here is not without its
shortcomings. The initial jig design was intended to evenly sample
the Bragg curve. However, because of the gradual increase in LET
along the entrance plateau, followed by the rapid rise proximal to
and just beyond the Bragg peak, the current jig design resulted in
oversampling of low-LET points (, 5 keV/mm) and undersampling
of LETs in the range of 5–10 keV/mm. Ideally, the design of the jig
could be optimized for uniform LET sampling. The increased
throughput gained by using the 96-well format comes at the cost of
limiting the maximum number of cells that can be seeded without
substantial colony overlap in high-SF plates to about 20014. The seed-
ing density limitation restricts the range of measureable SFs, making
achievable doses cell line-dependent. The infrastructure required for
the high-throughput method is also greater than for the standard
method and may not be universally available. The influence of the
bystander effect on the clonogenic assay is unclear, so we cannot
comment on any expected differential effects between the standard
and high-throughput method36.
While no studies have been reported that demonstrate a method to
map the biological effect of protons with this type of throughput, other
groups have done similar rigorous investigations using traditional
clonogenic assays to map combined LET-dose effects11–13,37. As prev-
iously noted, direct comparisons between studies are difficult because
of differences between experiments; however, general observations can
be made. Although recent studies have indicated that RBE and LET
scale linearly, our results suggest that the relationship between LET
and biologic effectmay not be so straightforward9,12,13. In both cell lines
tested, RBE increased rapidly with LET for values at and beyond the
Bragg peak (.10 keV/mm), but this trend was reduced for the LETs
measured from the entrance to the proximal portion of the Bragg peak
(, 10 keV/mm). All SF data fits from our work to the linear-quadratic
model produced curves with substantial ‘sub-lethal’ (b) components,
resulting in nonlinear dose-responses even at the highest LETs
(Table 1). Ubiquitous quadratic components are unusual, as an estab-
lished hallmark of SF after high-LET irradiation includesa-dominated
survival curves6,9,12,37,38. This observation results in a nonlinear res-
ponse between RBE and LET (Fig. 4a). One possible explanation is
that in many previous investigations, the LET values used to quantify
the relationship between RBE and LET are determined by averaging
over the broad spectrum of a passively scattered beam rather than the
narrow LET spectrum of a scanned beam. Because different energy
and LET spectra can coincidentally yield the same average value yet
result in substantially different biologic effects, the dose-averaged LET
used to estimate RBE may not correlate well with measured biologic
results39. This averaging may obfuscate the LET effect of cell kill,
especially at the end of range for charged particles, where the LET
has a wide spread. For example, in the 12th column of the plate in the
presented setup,MC simulation showed a proton LET range of 3 to 80
keV/mm, resulting in a dose-averaged LET value of about 19 keV/mm.
Narrow LET spectra should help to further elucidate the relationship
between RBE and LET.
The measured RBEs in the distal falloff region of the beam are
considerably higher than those typically reported in the literature as
well as the clinically used value of 1.1; however, such values are not
unheard of or the highest reported8,9,40. Our results imply that the
evaluation of biologic effect must ensure comprehensive character-
ization and suggest that additional studies using high-precision
methods are required to develop accurate models of biologic effect.
Although applying the results of in vitro assays to in vivomodels has
its own complications, clonogenic survival is by far the most com-
monly used andwell correlated cancer cell line assay for tumor control
probability, with substantial evidence establishing the relation
between the twomethods9,41–44. The actual translation of the presented
work towards preclinical evaluation of a biologically weighted treat-
ment in vivo requires substantial work even in the simplest murine
cancer model because of sensitivity to setup uncertainties and the
small scale of the anatomy. Meanwhile, a much larger knowledge
gap exists in the assessment of in vivo normal tissue radiation toxicity,
where cellular clonogenicity is but one of many factors affecting organ
response and function45–47. For complete biological optimization, nor-
mal tissue tolerances and responses must also be understood and
quantified in the appropriate biological context for effectivemodeling.
Whereas clonogenic survival was the primary endpoint in the
current study, this system can be easily modified to incorporate more
advanced biologic methods and models. In particular, 3D tissue cul-
ture holds great promise to produce settings that better recapitulate
an in vivo normal or tumor environment with corresponding tissue
imitation48–51. Our approach may also serve as a platform for investi-
gating other measures of biologic response as a function of LET,
including DNA damage response, cell signaling, or epigenetic altera-
tions. Moreover, the adaptation of other biologic models, facilitated
by the high-content approach, will allow functional assays of surviv-
ing cells, which could be useful for investigating radiation-induced
adverse effects on normal tissues.
Clinical investigations in Europe and Asia have sparked interest in
the use of heavier ions for cancer therapy, with the rationale that the
higher RBE of heavy particles may be particularly valuable for over-
coming the resistance of such tumors to photon irradiation5,52. The
physical properties of protons have generally driven the worldwide
expansion of proton therapy centers, but the inherent biologic differ-
ences between photon and proton beams have not been capitalized
on to date. The LET values for the scanned proton beams in the
current study are moderate in comparison to those for heavier ions.
Interest in carbon ion therapy has increased because carbon ions
have higher LET and higher biologic effectiveness, which could be
useful for radiation-resistant tumors. However, the biologic uncer-
tainties associated with heavy particles may be even greater than
those of protons. Moreover, both the physical and biologic charac-
teristics of protons and carbon ions may not make them the best
particles for clinical use. Rather, intermediate particles may hold the
greatest potential. Expanding the techniques developed here for use
with other ion sources (helium, carbon, oxygen) would allow con-
struction of a data matrix describing the interrelation of dose, LET,
and biologic effect. In conjunction with computer modeling of phys-
ical properties, having such data could allow predictions of the bio-
logic effect of other particles, which in turn could allow the most
favorable particles to be identified before the costly construction of a
therapy facility.
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Conclusion
Currently, in proton treatment planning, variable biological effec-
tiveness is not formally accounted for; only physical properties are
considered. Newer delivery technologies, such as spot scanning,
allow the delivery of individually heterogeneous treatment fields by
using techniques such as IMPT. In principle, optimization of IMPT
could incorporate variable biological effectiveness to produce dose
distributions in which protons with high biological effectiveness
preferentially deposit dose in the tumor and the ones that pass
through normal tissues are preferentially of low biological effective-
ness. However, the substantial uncertainties associated with existing
RBE data may preclude the development of accurate biologic models
for use in such applications. By incorporating data generated using
systems such as that described here, development of more accurate
models and optimization of IMPT based on RBE may be feasible. In
theory, this could enhance the therapeutic potential of particle ther-
apy for numerous types of cancer.
Methods
Designing an irradiation device with Monte Carlo simulation. We used a
calibrated and experimentally validated MC system based on the Geant4 toolkit to
design the experimental device53,54. Three versions of Geant4 (9.5.p02, 10.0 and 10.1),
with the pre-packaged FTFP_BERT (version 1.3 and 2.0) physics list, were tested and
no differences were found for therapeutic proton simulations. The characteristics
of proton beams entering the nozzle (e.g., energy, angular, and spatial spread) were
fine-tuned so that the computed depth dose and beamlet profiles matched the
corresponding measured data55. The thickness of each step of the irradiation jig
(Fig. 1f) was selected from a 79.7-MeV spot-scanning beam depth-dose and depth-
LET distribution curves in a Lucite phantom. The device was fabricated with a high-
accuracy (63 mm) milling machine. The original template was a cuboid block
(21319311 cm3) of Lucite.
Monte Carlo Dose and LET calculations in biological samples.A 5-mm cell layer in
each well in the 96-well plate was considered to be the target for dose and LET
calculations. Biologic effect is commonly assumed to be a function of dose-averaged
LET (LETd), which was the case in this report as well. The number of primary source
protons was set to 1.1x109 to ensure that the statistical uncertainty in the calculated
dose and LET values in the wells was 6,1%. LET was calculated on a step-by-step
basis in the particle tracking process. The energy deposition e over each proton step l
within the cell layer was scored. Because of the stochastic nature of energy deposition
by ionizing radiations, e/l was treated as a random variable form of LET. The
probability distribution of e/l was scored during the simulation to evaluate the
statistical uncertainty of LET calculation. In calculating LETd, e was treated as the
dose weighting factor of each e/l of protons for each cell layer. A dynamic MC
technique was used to simulate magnetic steering of the proton beamlet56. All MC
simulations were carried out on our institutional high-performance computing
cluster and the Lonestar cluster at the Texas Advanced Computational Center.
Comparison of energy spectra for matching scattered and scanned proton beams.
To illustrate the importance of using the scanning beam in contrast with the previous
practice of using passively scattered beams, we selected a passively scattered beam of
120MeV, which was broadened laterally with scatterers to form an 18 3 18 cm2 field
and modulated longitudinally by a range modulation wheel to form an SOBP 3 cm
wide. Finally, the beam was passed through the range shifter to achieve a range equal
to that of the 79.7-MeV spot-scanning beam that we used for the biology experiments.
Three points at depths of 2.15 cm, 4.0 cm, and 4.75 cm (positions A, B and C in
Fig. 1a–c and Supplementary Fig. 1) along the beam path were selected to calculate
and compare the proton kinetic energy spectra.
Hitachi proton therapy system. Proton irradiation was done with the scanning beam
gantry of the synchrotron and the Hitachi ProBeat delivery system (Hitachi, Ltd.,
Tokyo, Japan) at the Proton Therapy Center in Houston57. This delivery system can
provide 94 discrete energies ranging from 72.5 MeV to 221.8 MeV55,58. It uses a step-
and-shoot scanning technique in which the beamlet stops at a specified point and
delivers the specified number of monitor units and then moves to the next position.
Beam characteristics and scan patterns. The above-mentioned monoenergetic
scanning beam of 79.7 MeV (range 4.8 cm in water and 4.1 cm in Lucite), with a spot
of size 3.3 cm full-width-at-half-maximum in air at isocenter, was used for proton
irradiation55. A 20 3 20 cm2 area was scanned uniformly. It had a 12 3 13 cm2
uniform high-dose region to ensure the wells in the plate periphery were sufficiently
far from the penumbra to be affected by the lateral fall-off at the field edges
(Fig. 2a&b). The spacing between spots was set to 1 cm in the isocenter plane. The spot
intensity can be set to between 0.005 and 0.04 monitor units; we chose the maximum
value for this study.
We used the rotational gantry with beam incident upon the bottom of the plate
from below to minimize uncertainties arising from variability in the thickness of the
fluid layer above the cells, setup, and scattering from well walls. Different incident
dose levels were achieved by using multiple repaintings of the target plates with the
scan patterns. The incident dose per repainting is determined through a calibration
process described below. The relative dose levels per column in the 96-well plate were
always maintained (Fig. 1e) to be the same for all irradiation experiments.
System calibration and verification.We calibrated the system by using a calibrated
plane-parallel ion chamber irradiated under reference conditions that excluded the
jig. The dose at the calibrated chamber position under identical conditions was also
calculated by MC simulations. The doses calculated in wells by MC simulations were
normalized to the dose at the reference point. The calibration factor determined in
this way led to the delivery of 2.6 cGy 6 0.1% per painting (requiring 17.64 monitor
units) to the cell layer in column 1 in the presence of the jig. Each time before a set of
cell irradiation experiments were done, quality assurance was done to ensure that the
specified dose levels would be delivered.
Positioning of the experimental devices. The geometric setting of the devices and
samples was identical for all experiments. The jig, with the three films on top of it, is
inserted into a holder, which is placed in the last downstream snout slot. The snout
end was set to the same value, 9.1 6 0.1 cm, for each irradiation, such that the top of
the jig, where the biologic samples sit, was positioned at the isocenter plane (verified
by laser cross markers from two orthogonal directions).
Sensitivity analysis of experimental setup uncertainties. The Lucite jig, three EBT3
films, and well plate bottom constitute the energy-attenuating components for
protons before the cell layer. Hence, theMC-calculated accuracy of the delivered dose
and LET values depends on the thickness, chemical composition, and density of these
materials, especially for wells located near the end of the beam’s range.
Notably, given the geometry we use and the uniformity of the field of irradiation,
the accuracy of the dose delivered to the samples is insensitive to small changes in
position longitudinally or laterally relative to the beam. It is almost entirely a function
of precision of the thicknesses of the jig steps, well plate, films, and the accuracy of the
knowledge thematerial densities and compositions. Because we used the same jig and
films for all experiments, they do not contribute to random uncertainties, but they
may contribute to systematic uncertainties. However, since the jig was fabricated with
a high-accuracymillingmachine and the vendor-quoted uncertainty in film thickness
is very small (Supplementary Table 2), the overall systematic uncertainty in dose was
estimated to be negligible. However, the scattering properties of the jig were verified
by measuring the dose and range of the transmitted beam using with films and ion
chamber and comparing the results with MC simulations.
Because large numbers of plates were used, manufacturing variability in the
thickness of the well bottom and its composition could contribute non-negligible
uncertainty to dose in the high-gradient distal fall-off region. The chamber and MC
simulations each contributed less than 61% to uncertainty.
Parameters used for estimating uncertainties are given in Supplementary Table 2.
The nominal density of the jig material and 96-well plate material was set to 1.19 and
1.09 g/cm3 59,60. The estimated uncertainties, dominated by the random component,
are given in Supplementary Table 3. The highest uncertainties correspond to the high-
dose gradient at the distal edge.
TheMC-calculated dose and LET using the nominal valuewere treated as themean
values (Fig. 1e). The average deviation from the nominal with lower and upper ranges
of setups was treated as the uncertainty in the nominal value to yield the uncertainty
in dose and LET values (error bars in Fig. 1e, Supplementary Table 3). The effect of
uncertainties on protons energy spectra in three of the columns of the 96-well plate
are depicted in Supplementary Fig. 2.
Biologic sample preparation, irradiation, and processing. H460 and H1437
NSCLC cells were cultured in RPMI 1640 medium with 10% fetal bovine serum and
1% penicillin-streptomycin-L-glutamine at 37uC and 5% CO2. Cells were counted
using an automated cell counter and seeded at concentrations ranging from 100–2000
cells per well for the standard 6-well clonogenic assay and at 100 cells per well when
using the 96-well format. Plating reproducibility was ensured by using a BioTek
MultiFlo FX Microplate Dispenser for automated and rapid cell plating. Cells were
allowed to attach and stabilize in culture for 8–10 hours before irradiation. Plates were
brought into the treatment room one at a time for irradiation and immediately
returned to culture after exposure. Control plates were handled identically to
treatment plates but not irradiated. Two plates per dose level were irradiated,
resulting in 16 replicates per LET-dose combination. After colonies formed (at 5 days
for the H460 cells and 7 days for H1437 cells), cells were fixed and stained with 0.5%
crystal violet inmethanol. High-content automated laser confocal analysis with an IN
Cell Analyzer 6000 was used to identify viable colonies containing$50 cells. Briefly,
using a 4 3 objective, four overlapping fields per well were obtained and the GE
Developer v1.9 software used to create a composite. Colonies and cells were identified
with masks generated from object filters. Cells were linked to colonies, and only
colonies containing 50 or more cells were scored. The excitation wavelength was 640
nm (red) and the emission wavelength was 706 nm (Cy5). The 4 3 lens has a 0.20
numerical aperture. The IN Cell uses a 5.5-Mp sCMOS camera (2560 3 2160 pixels)
with a 6.5-mm pixel size. We defined the limit of detection for a clonogenic screen
assay as 1 colony per well or an SF of 1/(cells plated*plating efficiency). Dose levels
where the aggregate SF was lower than the limit were omitted from analysis. SFs were
analyzed by normalizing the number of counted colonies at a given dose by the plating
www.nature.com/scientificreports
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efficiency and by fitting the obtained data to a linear-quadratic model using weighted
non-linear regression.
Dose-LET-dependent cH2AX foci formation after proton irradiation was exam-
ined by plating cells into a glass-bottom microplate, irradiating them using the high-
throughput system, and returning to culture. Two hours after irradiation, cells were
fixed with 4% paraformaldehyde in phosphate buffered saline (PBS). The fixative was
removed and cells were washed in PBS 3 times before permeabilization with 0.5%
Triton X-100/PBS. Permeabilized cells were then blocked with a 5% goat serum/0.3%
Triton X-100/PBS solution. For primary labeling, the cells were incubated with a
murine cH2AX antibody (1:1000, clone JBW301, EMD Millipore) in 1% bovine
serum albumin (BSA)/0.1% Triton X-100/PBS. Cells were then washed 3 times with
0.1% Triton X-100/PBS and incubated with AlexaFluor 488-labeled goat anti-mouse
antibody in 1% BSA/0.1% Triton X-100/PBS (1:1000, Life Technologies). The cells
were washed again with 0.1% Triton X-100/PBS before mountingmediumwas added
with the fluorescent dye 4’,6-diamidino-2-phenylindole (DAPI). Plates were imaged
on an Olympus IX81microscope using a 40x water immersion objective. The average
number of cH2AX foci per nucleus was determined by using CellProfiler (Broad
Institute) to identify DAPI-labeled nuclei as image masks and quantify the number of
associated cH2AX foci. Images having the same average and median number of foci
per nucleus matching the respective condition’s overall pooled value were selected as
the representative images.
Statistical analyses. Statistical analyses were done using GraphPad Prism 6.0. SF data
are shown on a semilog scale as mean 6 standard error of the mean. Data were fit
using a weighted (1/Y)-nonlinear regression to the linear-quadratic model. The extra
sum-of-squares F test was used to compare clonogenic survival curves as a function of
LET. The cH2AX foci data are shown as mean 695% confidence interval. The
average numbers of cH2AX foci for each condition were tested for statistical
significance by the Mann-Whitney unpaired t test. RBE standard deviations were
calculated by propagating the standard error of the a and b fits.
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